Mark Reisenauer is senior vice president of the oncology business unit of Astellas. In this role, he is responsible for commercial activities supporting marketed products, Astellas' co-promotion partners and commercial planning for early stage oncology development compounds. Mark is a member of the Astellas US Management Committee.
Mark joined Astellas in 2011 as vice president, sales and marketing, oncology, where he led commercial activities supporting oncology products, Tarceva and the launch of Xtandi.
Prior to joining Astellas, Mark served as senior vice president and chief commercial officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning and commercial launch planning. Previously, Mark held various sales and marketing leadership roles at Abbott, Pharmacia, Bristol-Myers Squibb and AstraZeneca.
Mark experienced firsthand the complexity of navigating cancer care while his father battled head and neck cancer. After losing his father, he has dedicated his energy toward cancer care innovation.
Mark earned a bachelor’s degree in political science from the University of Wisconsin.